(NASDAQ: DYN) Dyne Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Dyne Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast DYN's revenue for 2026 to be $920,446,398, with the lowest DYN revenue forecast at $540,602,212, and the highest DYN revenue forecast at $1,300,290,584. On average, 5 Wall Street analysts forecast DYN's revenue for 2027 to be $12,793,778,138, with the lowest DYN revenue forecast at $3,094,236,345, and the highest DYN revenue forecast at $26,522,229,048.
In 2028, DYN is forecast to generate $44,338,344,000 in revenue, with the lowest revenue forecast at $24,469,363,280 and the highest revenue forecast at $61,456,513,043.